8229 Boone Boulevard
United States - Map
CEL-SCI Corporation is engaged in the research and development of drugs and vaccines. The companys lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. Multikine is also being used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. In addition, it is developing Ligand Epitope Antigen Presentation System (LEAPS), a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, is developing a peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
|Mr. Maximilian De Clara ,
Founder, Chairman and Pres
|Mr. Geert R. Kersten Esq.,
Chief Exec. Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer and Director
|Ms. Patricia B. Prichep ,
Sr. VP of Operations and Corp. Sec.
|Dr. Eyal Talor Ph.D.,
Chief Scientific Officer
|Dr. Daniel H. Zimmerman Ph.D.,
Sr. VP of Research - Cellular Immunology
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|